---
title: "Neurogene delays quarterly report for period ended September 30, 2024"
url: "https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-11-14"
section: "Distress"
tickers: "NASDAQ:NGNE"
source: "https://www.sec.gov/Archives/edgar/data/1404644/000140464424000094/ngne-form12bx25q32024form1.htm"
summary: "The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days."
---

By the aibio.space news desk.

Sources

- [Neurogene Inc. NT 10-Q (2024-11-14)](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000094/ngne-form12bx25q32024form1.htm)

[NGNE](https://aibio.space/companies/neurogene/)

2024-11-14

# Neurogene delays quarterly report for period ended September 30, 2024

Tickers [NGNE](https://aibio.space/companies/neurogene/)

The company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.

## Key facts

- **Company**: Neurogene Inc. (NASDAQ: NGNE)

- **News type**: Distress

- **Primary source**: [Neurogene Inc. NT 10-Q (2024-11-14)](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000094/ngne-form12bx25q32024form1.htm)

*The stone facade of a federal building. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Neurogene Inc. told the SEC on November 14, 2024 that it cannot file its quarterly report on Form 10-Q for the period ended September 30, 2024 within the prescribed time, according to a [notification of late filing](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000094/ngne-form12bx25q32024form1.htm).

The notice, filed on Form 12b-25, gives a company a short extension when it cannot finish a periodic report on schedule without unreasonable effort or expense. For a quarterly report, the extension runs to the fifth calendar day after the due date.

Neurogene said it has substantially completed the preparation of the report. But it said it "is experiencing delays due to recent developments that have diverted significant management time and internal resources" from its process for reviewing and completing its financial statements and related disclosures.

The company said it needs additional time to finalize the information to be included in the report. It expects to finalize its review and file the report on or before the fifth calendar day following the prescribed due date.

Neurogene said it has filed all other periodic reports required during the preceding 12 months. It does not expect a significant change in results of operations from the same period of the last fiscal year.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

NGNE

Neurogene Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Neurogene delays quarterly report for period ended September 30, 2024", 2024-11-14, https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/